EMPower: Electronic Media Powering Positive Health Changes in Youth
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overweight or Obese
- Speaks English
Exclusion Criteria:
- No smart phone / smart phone data plan
- Not willing to send/ receive text messages or download and use the study applications
- Neurological impairment/ developmental delay
- New / changes in anti-hypertensive medication or medication known to affect blood pressure within the last 6 months
- Prior diagnosis of congenital heart disease or cancer
- Pregnancy
- Taking medication with weight gain as a side effect
- Taking medications for weight loss/ participation in another weight loss program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Electronic Media Application
Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
|
Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
|
|
Active Comparator: Control
Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in adiposity as measured by change in BMI z-score
Time Frame: 6 months from date of randomization
|
6 months from date of randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in clinic systolic blood pressure
Time Frame: 6 months from date of randomization
|
6 months from date of randomization
|
|
Change in left ventricular mass index
Time Frame: 6 months from date of randomization
|
6 months from date of randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Tammy M Brady, M.D., Ph.D, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00065277
- 1K23HL119622-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
NCT04863508RecruitingHypertension,Essential | Hypertension, Masked
-
NCT05395403CompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White Coat
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07598760Not yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEF
-
NCT07577973Not yet recruiting
-
NCT07399912Enrolling by invitationHypertension,Essential
-
NCT07363447CompletedHypertension | Arterial Hypertension | Systemic Hypertension
-
NCT07566650Not yet recruiting
-
NCT07486453Not yet recruitingPrimary Hypertension
-
NCT07147595CompletedHypertension (HTN) | Hypertension Arterial
Clinical Trials on Electronic Media Application
-
NCT06327022CompletedQuality of Life | Mental Health | Dementia Caregivers
-
NCT03712267CompletedDepression | Anxiety Disorders | Electronic Media
-
NCT03925038CompletedDepressive Disorder | Anxiety Disorders | Bipolar Affective Disorder
-
NCT04617431CompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1
-
NCT02610946UnknownKidney Transplantation
-
NCT07561957RecruitingProteinuria | Chronic Kidney Disease | Tuberous Sclerosis Complex | Nephrotic Syndrome | Cancer Survivors | Blood Pressure Control | Congenital Anomalies of the Kidneys and Urinary Tract | Sickle-Cell Nephropathy
-
NCT03867045TerminatedMetastatic Renal Cell Carcinoma Treated With Cabozantinib
-
NCT06396598RecruitingMalignant Thoracic Neoplasm
-
NCT03199196Active, not recruiting